HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: A “true-or-false game”

HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: A “true-or-false game”
Francesco Paolo Russo, Savino Bruno, Fabio Farinati

DOI: http://dx.doi.org/10.1016/j.dld.2017.01.159

Digestive and Liver Disease
Accepted Manuscript

Data on the long-term outcome after antiviral therapy with Peg-Interferon and Ribavirin in patients with hepatitis C infection (HCV) and cirrhosis, who are at increased risk of developing liver decompensation (LD), hepatocellular carcinoma (HCC) and liver related death, showed that HCV eradication reduces both liver-related and non-liver-related mortality [1], thus leading to a life-expectancy similar to that of the general population [2]. The clinical benefit of HCV eradication is more significant in patients with compensated cirrhosis and without clinically significant portal hypertension (PH) who do not develop LD and rarely HCC [3].

Download Full Text PDF

Link To Full Text Article 

I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading about the treatment and management of hepatitis C.

Updated February 2017
Liver Cancer After Treatment For Hepatitis C
​Research demonstrates that while SVR markedly reduced liver-related complications and liver cancer, some long-term risk for liver cancer remained in those who were cured of Hepatitis C. But after direct-acting antiviral therapy does the risk of developing liver cancer increase?